Bill · S. 3522· Senate(119-S-3522)
No Red Tape For Addiction Treatment Act
- Introduced
- 12/17/2025
- Last activity
- 12/17/2025 — Read twice and referred to the Committee on Finance.
- Sponsored by
- Maggie Hassan
- Cosponsors
- - 0 - 1
- Introduced
- In Committee
What this bill would do
This bill is known as the No Red Tape For Addiction Treatment Act. It requires State Medicaid programs to provide at least one formulation of each type of medication used to treat opioid use disorder without prior authorization or dosage limitations. This coverage must include a long-lasting and injectable formulation if available. The bill also requires the Medicaid and CHIP Payment and Access Commission to submit a report to Congress regarding utilization management controls for this treatment within one year of the bill's enactment. These changes generally apply to medical assistance provided one year after the date of enactment, with some exceptions for states that need to pass new legislation.
Yes· 3 of 20
Does this do more about addiction and overdose deaths?+9
Directly addresses the opioid crisis by streamlining access to essential treatment medications and mandating a congressional report on utilization barriers.
Would households on low incomes be better off under this?+8
Low-income individuals reliant on Medicaid will experience significantly reduced roadblocks in obtaining addiction treatment.
Does this make health care easier to get in general?+8
Significantly improves access to medication-assisted treatment for opioid use disorder by eliminating prior authorization and dosage caps.
The opposite
Does this leave more decisions to the states?-2
Limits states' ability to use prior authorization and dosage limitations on certain addiction medications within Medicaid.
Who it would affect, and how
Potential Positive Impacts for People
-
Section 2 amends the Social Security Act to require State Medicaid plans to provide at least one formulation of each drug and biological product for treating opioid use disorder without prior authorization or dosage limitations. This is positive because it removes roadblocks for individuals trying to get addiction treatment medications.
-
Section 2 also specifies that the required coverage must include a long-lasting and injectable formulation if available. This benefits people by ensuring access to convenient treatment options without needing prior approval.
-
Section 3 requires a report to Congress from the Medicaid and CHIP Payment and Access Commission assessing how management controls and other policies create administrative burdens for clinicians and impede patient access to medication-assisted treatment. This is a positive step to hold officials accountable and examine barriers to care.
Potential Negative Impacts for People
- Based on the provided text, there are no explicitly stated negative impacts or burdens for individuals or groups of people in the United States.
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Hover a score for the reason it gave.
- Demographic And Interest Groups
- Good For Low Income Households+8Good For Middle Aged+6Good For Native Americans+6Good For Young Adults+6Good For African Americans+5Good For Hispanic Americans+5Good For Men+5Good For White Americans+5Good For Women+5Good For L G B T Q Community+4Good For Seniors+4Good For Asian Americans+3Good For Children+3Good For Middle Class Households+2
- Healthcare
- Improves Opioid Crisis Response+9Improves Healthcare Access+8Increases Medicaid Funding+7Reduces Prescription Drug Costs+5
- Governance And Ideology
- Improves Government Transparency+5Increases Federal Power+4Increase States Rights-2
- 12/17/2025
- Read twice and referred to the Committee on Finance.
- 1 Cosponsor added.
- Introduced in Senate
James JusticeRepublican · West Virginia